Lv61
3158 积分 2024-08-02 加入
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
13天前
已关闭
Circadian autophagy drives iTRF-mediated longevity
1个月前
已完结
717 - Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects
5个月前
已完结
717 - Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects
5个月前
已完结
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
6个月前
已完结
Engineering the IL‐4/IL‐13 axis for targeted immune modulation
6个月前
已完结
IL-13 Induces Skin Fibrosis in Atopic Dermatitis by Thymic Stromal Lymphopoietin
6个月前
已完结
Investigational anti IL-13 asthma treatments: a 2023 update
6个月前
已完结
Molecular Mechanisms of Atopic Dermatitis Pathogenesis
7个月前
已完结
Trends in atopic dermatitis prevalence among the Chinese population (1990–2021) with projections for 2022–2030
7个月前
已完结
皖公网安备34019202002308
